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Abstract
Background: A few tau immunotherapies are now in clinical trials with several more likely to be initiated in the
near future. A priori, it can be anticipated that an antibody which broadly recognizes various pathological tau
aggregates with high affinity would have the ideal therapeutic properties. Tau antibodies 4E6 and 6B2, raised
against the same epitope region but of varying specificity and affinity, were tested for acutely improving cognition
and reducing tau pathology in transgenic tauopathy mice and neuronal cultures.
Results: Surprisingly, we here show that one antibody, 4E6, which has low affinity for most forms of tau acutely
improved cognition and reduced soluble phospho-tau, whereas another antibody, 6B2, which has high affinity for
various tau species was ineffective. Concurrently, we confirmed and clarified these efficacy differences in an ex vivo
model of tauopathy. Alzheimer’s paired helical filaments (PHF) were toxic to the neurons and increased tau levels in
remaining neurons. Both toxicity and tau seeding were prevented by 4E6 but not by 6B2. Furthermore, 4E6
reduced PHF spreading between neurons. Interestingly, 4E6’s efficacy relates to its high affinity binding to
solubilized PHF, whereas the ineffective 6B2 binds mainly to aggregated PHF. Blocking 4E6's uptake into neurons
prevented its protective effects if the antibody was administered after PHF had been internalized. When 4E6 and
PHF were administered at the same time, the antibody was protective extracellularly.
Conclusions: Overall, these findings indicate that high antibody affinity for solubilized PHF predicts efficacy, and
that acute antibody-mediated improvement in cognition relates to clearance of soluble phospho-tau. Importantly,
both intra- and extracellular clearance pathways are in play. Together, these results have major implications for
understanding the pathogenesis of tauopathies and for development of immunotherapies.
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Background
Tau immunotherapy was a logical approach following
the success of amyloid-β (Aβ) immunotherapies in
mouse models but faced resistance as tau was not
thought to be accessible to antibodies. However, tar-
get engagement was feasible both intra- and extracel-
lularly. Antibodies against tau and other targets have
been detected intraneuronally [1, 2], and studies over
the last several decades suggested that all amyloid
diseases may be transmissible between cells under
proper conditions [3]. Following our initial report of
active tau immunotherapy leading to clearance of tau
aggregates in transgenic mice with associated func-
tional improvements, several studies by us and others
have confirmed and extended these findings (reviewed
in [4, 5]). Concurrently, spreading of tau pathology
between cells in culture and via anatomically con-
nected brain regions in animals has now been shown
by several groups (reviewed in [6, 7]). A few phase I
trials have now been initiated on active and passive
tau immunotherapies [5]. The hope is that this
approach may be more effective than targeting Aβ in
the later stages of the disease as tau pathology corre-
lates better with dementia than Aβ plaques [8].
Although the efficacy of tau immunotherapy has been
confirmed in various models, our knowledge of the
mechanisms involved is rather limited. Tau antibodies
have now been detected intraneuronally in several stud-
ies by a few groups [1, 9–14] and such uptake shown to
be necessary for acute tau clearance [10]. However, some
antibodies do not appear to be taken up in appreciable
amounts and are likely to primarily work extracellularly
[15–17]. Such differences in uptake are well known in
other immunotherapy fields and may be related to anti-
body charge [18, 19]. Several tau epitopes have been suc-
cessfully targeted using a similar study design (reviewed
in [5]). However, very limited knowledge exists regarding
the ideal affinity of antibodies and which tau species they
should bind to be effective in promoting clearance of
pathological tau protein. It is conceivable that very high
affinity antibodies, at least against certain epitopes, may
promote tau assembly or prevent their disassembly.
Most recently, we have developed a novel set of
monoclonal antibodies targeting the phospho-serine
396,404 region. Two of these, 4E6 and 6B2, enter
neurons and co-localize with tau [11]. In brain slice
cultures, both antibodies reduce soluble phospho-tau
after 6 weeks of treatment, and 4E6 has been shown
to acutely reduce tau levels in primary neurons via an
intracellular mechanism [10, 11]. The two antibodies
display different binding characteristics with 4E6
being phospho-selective and 6B2 having conform-
ational properties influenced by phosphorylation and
an apparent higher affinity for tau [11].
We tested the efficacy of these antibodies acutely
in vivo and their ability to prevent toxicity, seeding and
transmission of tau pathology in primary neuronal
cultures, using paired helical filaments (PHF) isolated
from an Alzheimer’s brain. In addition, we examined
whether neuronal uptake of antibody was necessary for
efficacy, and what role timing of antibody addition had
on the observed mechanism of action. Our data indi-
cates that 4E6 acutely improves spatial learning and
memory, which is associated with a reduction in soluble
phospho-tau protein. Furthermore, 4E6 prevents tox-
icity, seeding and transmission of tau pathology even
though it binds poorly to most forms of tau, whereas
6B2 is ineffective although it binds strongly to most
forms of tau. These unexpected results are likely to have
major implications for the clinical development of tau
immunotherapies, and can be explained by 4E6’s high af-
finity for solubilized PHF, whereas the ineffective 6B2
binds primarily to aggregated but not to solubilized
PHF. Hence, affinity for particular forms of tau predict
efficacy. Further, whether the antibody is working out-
side or inside the neuron depends on the timing of PHF
and antibody addition. Antibodies with access to both
intra- and extracellular pools of pathological tau protein
are likely to be more efficacious than antibodies acting
only within one compartment.
Results
In vivo studies
4E6 acutely improves cognition in htau mice and reduces
soluble phospho-tau protein, whereas 6B2 does not affect
cognition or tau levels
At 11–12 months of age, the htau mice were assigned to
control and treatment groups with similar cognitive
(CFSM test) and motor status (Rotorod and Open Field).
After baseline behavioral assessment, the mice received
three antibody injections over a two week period and
were re-evaluated on the same tests in addition to a fear
conditioning test, followed by brain extraction for tissue
analysis.
Behavior
As shown by trial errors, acute treatment with 4E6 led
to significant improvements in spatial learning and
memory in the CFSM test (48 % fewer errors in post-
test vs. pre-test; 13.6 (average errors) ± 1.2 (SEM) to 7.1
± 0.9, p < 0.01), whereas the IgG control mice did not
improve compared to their pre-injection performance
(Fig. 1a) These differences were not gender related. 4E6
treated males (52 % fewer errors; 14.6 ± 0.8 to 7.0 ± 1.4,
p < 0.01) performed similar to 4E6 treated females (44 %
fewer errors; 12.7 ± 2.2 to 7.1 ± 1.2, p < 0.05). Repeated
measures, two-way ANOVA revealed a treatment effect
(p = 0.0018), but not a gender effect (p = 0.5145).
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Conversely, 6B2 treatment did not result in improve-
ments in this test (Fig. 1b). Neither antibody showed
benefits in a fear conditioning test (Fig. 2a, b). Both
treatment groups of mice performed similarly to IgG
controls in motor function tests (rotor rod and open
field tests, Fig. 2c–j), suggesting that the 4E6-mediated
improvements in cognitive functions were direct results
of the immunization, but not secondary effects from
motor function changes.
Immunohistochemistry, western and immunoblot analyses
Rather mild tau pathology was detected in PHF-1 or
MC1 stained brain sections (Additional file 1: Figure
S1). PHF-1 stained sections had some neuropil stain-
ing but lacked cell body staining. Likewise, MC1
staining was limited, although a few intraneuronal tau
aggregates were evident at high magnification. This is
as expected as MC1 detects earlier tau pathology than
PHF-1. There were no apparent differences between
the treatment groups. Overall, we have observed a
slower development, and less extensive pathology in
this model compared to the initial report [20]. The
observed differences in pathology may be due to sev-
eral factors, such as a reduction in the transgene copy
number, promoter methylation, or the cleanliness of
the facility the animals are housed in. There may also
be selection effects, where animals with less pathology
produce larger litters and become overrepresented in
the colony. Other researchers have observed a lessen-
ing of pathological severity over time, or spontaneous
loss of phenotype in transgenic lines [21, 22]. Like-
wise, no significant differences were seen via Western
blot using CP27 in either the total tau low speed
supernantant, or in sarkosyl insoluble tau for either
antibody (Fig. 3a–d). Tau-5, an additional total tau
antibody, also showed no significant differences
(Fig. 3e, f ). However, acute 4E6 treatment signifi-
cantly reduced soluble PHF-1 reactive tau (48 % re-
duction; p = 0.037, Fig. 3g), whereas 6B2 did not
(Fig. 3h) . This beneficial effect of the therapy was
not gender related (two-way ANOVA; gender effect
(p = 0.905), and did not appear to be oligomer spe-
cific as T22 did not reveal any differences between
the 4E6 and IgG groups (Fig. 3i). Sarkosyl insoluble
fractions were also probed with PHF-1 and Tau-5, with no
significant differences seen between antibody and IgG
treated animals for either 4E6 or 6B2. Average chemilumin-
escent signal for PHF-1 in animals treated with 4E6
and control IgG were 582,276 ± 138,812 and 491,638 ±
165,340 (p = 0.50), and for Tau-5 616,980 ± 151,750 and
509,180 ± 154,157 (p = 0.67), respectively. The same
analyses were performed for 6B2 and IgG treated
mice with average chemiluminescent signal for PHF-1
being 327,492 ± 92,674 and 322,075 ± 84,285 (p = 0.84)
and for Tau-5 567,725 ± 179,647 and 549,867 ±
159,106 (p = 0.86), respectively.
For all blots prepared using low speed supernatant
samples, chemiluminescent signal was normalized using
GAPDH (Fig. 3). There was minor variation in some
samples, but GAPDH blots showed no significant differ-
ence between the control and treated groups. Two bands
are visible on the representative blot prepared from the
4E6 study, whereas only one band is visible in the 6B2
study. This is likely due to differences in running time
between blots.
Mechanistic in vitro and ex vivo studies
To further clarify the mechanisms of the positive effects
of 4E6 and lack thereof for 6B2, various in vitro and ex
vivo experiments were performed.
Fig. 1 Acute 4E6- but not 6B2 therapy improved spatial learning and memory in htau mice. a 4E6 immunized mice showed significant
improvements in Closed Field Symmetrical (CFS) Maze (48 % fewer errors, p < 0.01), compared to their pre-immunization performance,
whereas control IgG treated mice did not improve. When divided by gender, both males and females treated with 4E6 showed significant
improvement over their pre-treatment performance (52 and 44 % fewer errors, p < 0.01 and p < 0.05, respectively, see text for average and
SEM) Repeated measures, two-way ANOVA revealed a significant effect of treatment (p = 0.0018) but not of gender (p = 0.5145), indicating
that the results seen are not attributable to gender differences. In contrast, animals treated with IgG did not show improvement when all
animals were considered together, or when divided by gender. b 6B2 treated mice also did not improve in the same test. **: p < 0.01
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Incubation with AD-derived PHF induces toxicity in primary
neurons and 4E6, but not 6B2, prevents these effects
Primary neuronal cultures were prepared from JNPL3 mice
and exposed to human derived PHF in one of four dosing
conditions (Fig. 4a, b): PHF alone, PHF added 24 h before
antibody (PHF→Ab), PHF material and antibody added
concurrently (PHF +Ab), or antibody was added 24 h be-
fore PHF (Ab→ PHF). PHF was used at 1 and 10 μg/ml.
Its solubility was verified at the 10 μg/ml. No visible pellet
was seen at this concentration after 100,000 x g centrifuga-
tion for 60 min. Prior work by others indicates that PHF
can be soluble at least up to 100 μg/ml [23].
Fig. 2 Neither tau antibody led to benefits in a fear conditioning test or affected motor performance. a–j Treatment benefits were not
observed in a fear conditioning test for a 4E6 or b 6B2, which relies on different brain circuits than the navigational test, or in motor
tests (c-j), which were performed to verify that the cognitive benefits cannot be explained by confounding changes in motor
performance. As expected, mice from both treated and control groups generally performed better on their post-treatment motor tests
because of their pre-treatment training. *: p < 0.05, **: p < 0.01, ***: p < 0.001. Stm: Short-term memory, Ltm: Long-term memory






4E6  IgG 4E6  4E6 IgG  4E6  IgG 4E675-
50-
6B2  6B2 6B2 6B2 IgG  IgG KO  IgG  75-
50-
c 4E6  IgG 4E6  IgG 4E6   KO  4E6  IgG75-
50- 50-





6B2  6B2 6B2 6B2 IgG  IgG KO  IgG  




































































































I g G 4 E 6
0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0






















IgG  IgG IgG 6B2 6B2 6B2 IgG 6B2




Ig G 6 B 2
0
5 0 0 0 0 0
1 0 0 0 0 0 0






IgG  IgG 6B2  6B2 6B2 KO  IgG IgG
4E6  4E6 IgG  4E6  IgG  4E6   IgG 4E6   
Fig. 3 (See legend on next page.)
Congdon et al. Molecular Neurodegeneration  (2016) 11:62 Page 5 of 24
Lactate dehydrogenase assay
Untreated control cells showed an 18 % increase in LDH
over 7 days, indicating that some normal cell loss
occurs.
PHF 10 μg Results from one-way ANOVA showed sig-
nificant treatment effect (p = 0.002; Fig. 4d). Addition of
10 μg/ml PHF resulted in a significant increase in LDH
levels relative to control samples at day 7 (a 67 % in-
crease above control, p < 0.01). In contrast, when 1 μg/
ml of 4E6 was added to the cultures together with the
PHF material (PHF + Ab group) or 24 h after PHF
(PHF→Ab), this increase was reduced from 67 % above
control to 12 and 15 %, respectively (p < 0.05 relative to
PHF alone). In both treatment paradigms, the groups
were not significantly different from control cells.
However, LDH levels in the Ab→ PHF group were
significantly higher than in the untreated cells (53 %
above control, p < 0.05), and did not differ signifi-
cantly from PHF alone treated samples. Hence, the
Ab→ PHF treatment approach for 4E6 was ineffect-
ive, in contrast to the PHF→ Ab and PHF + Ab para-
digms. In addition, all of the 6B2 treatment groups
had significantly higher LDH levels relative to un-
treated controls (69, 59 and 79 % above control for
the PHF + Ab, PHF→ Ab, and Ab→ PHF treatment
groups respectively, p < 0.05). None of the 6B2
groups differed significantly from PHF alone samples,
indicating that the 6B2 antibody was ineffective
under any of the paradigms in preventing PHF tox-
icity. IgG1 control did not influence PHF toxicity
under any of the treatment conditions, again con-
firming the specificity of the 4E6 effect to prevent
PHF toxicity.
(See figure on previous page.)
Fig. 3 4E6, but not 6B2, reduced soluble phospho-tau levels in htau mice. a, b Insoluble tau protein (sarkosyl pellet) levels were not altered in a
4E6 or b 6B2 immunized mice as detected by total human tau antibody CP27, compared to IgG controls. Similar results were obtained with total
tau antibody Tau-5 or phospho-tau antibody PHF-1 (not shown, see values in text). c–f Likewise, soluble tau levels (low speed supernatant; CP27,
Tau-5) normalized to GAPDH were not significantly altered in 4E6 treated mice compared to IgG control group. g, h Animals treated with 4E6
showed a significant reduction in levels of soluble PHF-1 reactive tau relative to IgG controls (48 % reduction, p = 0.037), while those treated with
6B2 showed no change. This beneficial effect of the therapy was not gender related (two-way ANOVA; gender effect: p = 0.905). i Also, the cogni-
tive benefits in the 4E6 group could not be explained by differences in T22 detected oligomeric tau as those levels did not differ between the
4E6 and IgG group (dot blot quantitation shown, similar results were seen on Western blots (not shown). *: p < 0.05
Fig. 4 PHF Characterization, dosing methods, and PHF induced toxicity as measured via LDH. a Immunoblot showing enriched human PHF tau (PHF-1
staining) derived from an Alzheimer’s brain. b Neurons were exposed to PHF under one of four dosing paradigms. PHF was added alone, 24 h prior to
antibody addition (PHF→ Ab), together with antibody (PHF + Ab), or 24 h after antibody (Ab→ PHF). Cells were washed with Neurobasal media
between each step, and collection began 24 h after the last treatment applied. c In cells treated with 10 μg/ml PHF, LDH signal averaged 67 % above
that of untreated controls (p < 0.01). 4E6 in the PHF + Ab and PHF→ Ab paradigms significantly reduced LDH compared to PHF alone, and were
comparable to untreated samples (11 and 15 % above control, p < 0.05), indicating that the antibody prevented toxicity. However, the Ab→ PHF was
not effective in reducing LDH signal (53 % above control) and showed no significant improvement over PHF alone samples. d All samples treated with
6B2 showed significantly higher levels of LDH relative to untreated controls (69, 59 and 79 % above control for the PHF + Ab, PHF→ Ab, and Ab→ PHF
treatment groups respectively, p < 0.05). None of the treatments with 6B2 reduced LDH relative to PHF alone. e IgG was also not effective in preventing
the increased LDH levels triggered by the addition of PHF. LDH in the PHF + Ab, PHF→Ab, and Ab→ PHF groups was increased to 80, 43 and 61 %
above control values (p< 0.05). None of the groups were significantly different from PHF alone. *: p < 0.05, **: p< 0.01, ***: p< 0.001
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PHF 1 μg As for 10 μg PHF, a one-way ANOVA re-
vealed significant treatment effect (p = 0.03; data not
shown). At the 1 μg/ml dose of PHF, LDH levels were
again, as with the higher dose, significantly higher than
in the untreated control cells although the toxicity was
not as severe (35 % above control, p < 0.05). As in the
higher dose samples, 4E6 in either the PHF + Ab or
PHF→Ab paradigms significantly reduced LDH levels
relative to PHF alone samples (7 and 15 % below control
values, p < 0.05 for both). IgG1 control did not signifi-
cantly influence PHF toxicity under any of the treatment
conditions (data not shown).
NeuN immunoblotting
In addition to LDH signal, toxicity was also examined
via immunoblotting with an antibody recognizing neur-
onal marker NeuN (Fig. 5a-c). For these and all subse-
quent immunoblots, untreated control cells served as
internal control because typical markers could not be
used due to the PHF toxicity.
PHF 10 μg Results from ANOVA showed a significant
effect of both treatment and time (p < 0.0001 for both).
When incubated with 10 μg/ml PHF, NeuN signal stead-
ily declined and was reduced 94 % relative to untreated
control samples by day 7 (Fig. 5d). As was the case with
the LDH samples, the PHF + Ab and PHF→Ab
paradigms for 4E6 (1 μg/ml) prevented PHF toxicity
(samples were 16 and 24 % above untreated control on
day 7, Fig. 5d) and did not significantly differ from
untreated control at any time point. Also as above, the
Ab→ PHF dosing method was not effective in prevent-
ing the loss of NeuN over the treatment period (93 %
loss), at each time point showed NeuN levels signifi-
cantly lower than control (p < 0.0001) and showed no
improvement over the PHF alone samples. As in the
LDH assay, neither 6B2 (Fig. 5e) nor IgG1 (Fig. 5f ) had
any effect on PHF induced toxicity, and did not signifi-
cantly differ from PHF alone.
PHF 1 μg Additional groups of neurons were incubated
with 1 μg/ml PHF and 1 μg/ml of 4E6 or control IgG1
(Fig. 6) and also probed with NeuN (Fig. 6a, b). As with
the higher PHF dose, the two way ANOVA results showed
a significant effect of treatment and time (p < 0.0001 and
0.007). A 30 % loss of NeuN signal relative to untreated
control cells was observed in the PHF alone group after
seven days in culture. PHF alone samples were signifi-
cantly lower than untreated controls at each time point
(p < 0.01-0.001). As in the 10 μg PHF experiments, the
PHF + Ab and PHF→Ab groups showed efficacy in
preventing the loss of NeuN, and at day 7 were com-
parable to untreated controls and significantly higher
that PHF alone samples (p < 0.01 for both at day seven,
Fig. 5 4E6, but not 6B2, prevented neurotoxicity induced by 10 μg/ml
PHF. a–c NeuN immunoblots from samples treated with 10 μg/ml PHF
alone and with PHF and 1 μg/ml a 4E6, B 6B2 or c control mouse
IgG1. d Quantitation of signal in samples treated with PHF alone and a
combination of PHF and 4E6. At 10 μg/ml, PHF alone reduced NeuN
levels by 94 % relative to untreated control cells (p < 0.0001). PHF +
Ab and PHF→ Ab paradigms resulted in NeuN levels significantly
higher than those incubated with PHF alone (116 and 124 % control,
p < 0.0001 for both) and were comparable to control levels. However,
the Ab→ PHF paradigm was ineffective and showed a significantly
reduced NeuN signal relative to control (93 % loss, p < 0.0001) and no
improvement over PHF alone samples. e 6B2 did not prevent NeuN
loss under any of the dosing conditions used. None of the groups
were significantly improved relative to PHF alone. f Similar to the 6B2
samples, the control IgG1 did not protect against the PHF induced loss
of NeuN and these samples were similar to the PHF alone group
Congdon et al. Molecular Neurodegeneration  (2016) 11:62 Page 7 of 24
Fig. 6c). The Ab→ PHF group also showed a decline in
NeuN levels (36 % decrease over seven days relative to
untreated controls, p < 0.05) comparable to PHF alone
samples, confirming the inefficacy of this approach. As
in the higher PHF dose samples, control mouse IgG1
(Fig. 6d) was ineffective in preventing toxicity under
any of the dosing conditions.
Together, the LDH and NeuN data consistently
show that tau antibodies can prevent the dose-
dependent toxicity triggered by exposure to misfolded
tau aggregates, but not all antibodies are effective.
4E6, but not 6B2, prevented toxicity, and then only
under certain conditions. When 4E6 is added prior to
PHF, it is possible that the relatively low level of tau
native to the neurons does not provide sufficient
targets to promote the retention of antibody that is
necessary to protect the cells.
In addition to both of the quantitative measures used
to assess toxicity, a qualitative visual inspection of the
cells was made prior to each collection. In untreated
cells, cell bodies appeared healthy with an extensive
network of processes. In contrast, PHF treated cells had
shrunken cell bodies, retracted processes, and debris
from dead cells was clearly visible under the microscope.
Further, media color provides an indication of the level
of cellular respiration occurring. When cultures were
healthy, the changing pH resulted in a shift towards a
more orange color. However, in cultures where cells
were dying, the media remained pink indicating limited
cellular activity. These PHF-induced changes were pre-
vented in 4E6-treated cultures.
4E6 treatment prevents changes in tau levels caused by
PHF exposure, whereas 6B2 has no effect
Total Tau
PHF 10 μg In addition to measures of toxicity, the
effect of PHF and antibody treatments on tau levels
was also investigated via immunoblot (Fig. 7a–c).
Similar to the NeuN results, a significant effect of
both dosing method and time were seen (p < 0.0001
for both). At the 10 μg/ml concentration, the total
tau levels in the PHF alone group showed an initial
decrease followed by a recovery (Fig. 7). However, by
day 7 total tau levels were reduced relative to control
cells (a 29 % decrease, p < 0.05). In contrast, the 4E6
PHF + Ab and PHF→Ab groups had significantly
higher tau levels (48 and 51 % above control, p < 0.01
relative to control, p < 0.001 relative to PHF alone,
Fig. 7d) than PHF alone. Again the 4E6 Ab→ PHF
group, or any dosing paradigm of the 6B2 (Fig. 7e)
and IgG1 (Fig. 7f ) groups were ineffective in prevent-
ing changes in tau levels at day 7 compared to PHF
alone cells.
Tau/NeuN When these results were normalized using
the NeuN values to take into account PHF toxicity, there
were again significant effects of treatment and time by
two-way ANOVA (p < 0.0001 for both). It became clear
that the remaining cells in the PHF and 4E6 Ab→ PHF
groups had significantly more tau than control cells at day
seven (a 5.6 and 5.5 fold increase at seven days, p < 0.0001
for both, Fig. 7g). In the 4E6 PHF +Ab and PHF→Ab
groups, adjusted tau levels were comparable to untreated
controls and significantly lower than the PHF alone sam-
ples (p < 0.0001 for both). All of the 6B2 (Fig. 7h) and
IgG1 (Fig. 7i) dosing groups did not differ significantly
from PHF alone, and were significantly higher than un-
treated cells by day 7 (p < 0.05-0.0001).
Fig. 6 Low dose PHF (1 μg/ml) reduced NeuN signal, and 4E6
prevented this toxicity. a, b NeuN immunoblots for samples treated
with 1 μg/ml PHF alone or 1 μg/ml PHF and 1 μg/ml a 4E6 or b
control IgG1. c Chemiluminescent signal was quantified and as in
the higher dose samples, exposure to PHF decreased NeuN signal
(30 % loss relative to untreated cells, p < 0.001) after 7 days. For 4E6,
the Ab→ PHF group also showed a decline in NeuN levels (36 %
decrease relative to control, p < 0.05) comparable to PHF alone
samples. Again the PHF + Ab and PHF→ Ab groups had significantly
higher NeuN levels at the end of the experiment (102 and 91 %
control values, p < 0.01 relative to PHF alone). d Mouse IgG1 was
ineffective in preventing NeuN loss under all of the dosing
conditions and did not differ significantly from PHF alone
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PHF 1 μg At the 1 μg/ml dose, the increased tau levels
were evident even before normalization with NeuN level
(Fig. 8a, b). Again a two-way ANOVA showed significant
dosing and time effects (p < 0.0001 for both, Fig. 8c).
PHF promoted significant increases in intracellular tau
(95 % above control, p < 0.0001) by experimental day 7.
The PHF + Ab and PHF→Ab were not changed relative
to untreated control and were significantly lower than
Fig. 7 4E6, but not 6B2, prevented increase in the tau/NeuN ratio caused by exposure to 10 μg/ml PHF. a–c Immunoblots probed with a pan-tau
antibody of samples incubated with PHF or PHF in combination with a 4E6, b 6B2 or c control IgG1. d Quantitation of total tau levels in samples
incubated with PHF and 4E6. With PHF alone, total tau levels decreased relative to control before recovering (29 % decrease at day 7). In contrast, samples
in the PHF + Ab and PHF→ Ab groups had significantly higher tau levels (48 and 51 % above control, p< 0.001 relative to PHF alone). Ab→ PHF samples
did not significantly differ from PHF alone. e After 7 days in culture, samples treated with PHF and 6B2 were not significantly different than the PHF alone
samples. f The IgG1 treated cells also did not differ significantly from PHF alone. g We then used the values obtained from the NeuN data to normalize
tau levels. Due to the substantial toxicity seen using LDH and NeuN immunoblotting, tau levels alone did not provide an accurate picture of the effects
of PHF exposure. Incorporating NeuN data allowed us to account for neuronal loss when assessing changes induced by PHF. Using this method, it
became evident that the remaining cells in the PHF group had significantly more tau (tau/NeuN) that control cells (5.6 fold increase, p< 0.0001). In the
PHF + Ab and PHF→ Ab groups, adjusted tau levels were comparable to control and significantly lower than the PHF alone samples (p< 0.0001). h
When NeuN levels were controlled for, all 6B2 treated groups had tau levels significantly higher that controls with no significant difference from PHF
alone group (p < 0.05-0.0001). i Controlling for NeuN did not alter the pattern of results seen in cells incubated with IgG
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the PHF alone samples (p < 0.0001 for both). IgG1
(Fig. 8d) was ineffective under all of the dosing
paradigms, as was the 4E6 Ab→ PHF treatment group.
Tau/NeuN Significant dosing and time effects were
found using two-way ANOVA (p < 0.0001 for both).
After normalizing tau levels with NeuN, again the PHF
alone cells had significantly increased tau levels relative
to control cells (1.6 fold increase, p < 0.0001 for both,
Fig. 8e). Only the 4E6 PHF + Ab and PHF→Ab groups
had significantly lower normalized tau levels compared
to the PHF alone group and did not differ from un-
treated control samples (p < 0.0001 for both). After 7 days
in culture, IgG1 samples did not significantly differ from
PHF alone (Fig. 8f ).
Phospho-Tau
PHF 10 μg In addition to total tau levels, we also assessed
the levels of tau phosphorylated at Ser199 (Fig. 9a–c).
Statistical analysis with two-way ANOVA revealed signifi-
cant effect of dosing method and time (p < 0.0001 for
both). Under the 10 μg/ml PHF conditions, PHF alone
and 4E6 Ab→ PHF samples had significantly reduced
phospho-tau levels relative to untreated cells at day seven
(34 and 54 % reduction, p < 0.05 and 0.001 respectively,
Fig. 9d). However, both the PHF +Ab and PHF→Ab
treatment groups had significantly higher phospho-tau
levels that the PHF alone group (p < 0.001 and 0.05 re-
spectively, Fig. 9d), and did not differ from untreated cells
at day 7. None of the 6B2 (Fig. 9e) or IgG1 (Fig. 9f) dosing
groups differed from PHF alone by experimental day 7.
Phospho-Tau/NeuN Correcting for NeuN levels to
take into account PHF toxicity, significant effects of
dosing method and time were seen using two-way
ANOVA (p < 0.0001 for both). PHF alone samples
showed higher levels of P-Ser199 tau (4.1 fold in-
crease at day 7, p < 0.0001). Phospho-tau levels in the
PHF + Ab and PHF→Ab groups were significantly
Fig. 8 Low dose PHF (1 μg/ml) increased the intracellular tau/NeuN ratio, which was prevented by 4E6. a, b Immunoblots for samples exposed
to PHF alone or with a 4E6 or b control IgG1, probed with a pan tau polyclonal antibody. c Quantitation of total tau levels shows that at 1 μg/
ml, PHF promoted significant increases in intracellular tau (95 % above control, p < 0.0001). For 4E6, the PHF + Ab and PHF→ Ab were
significantly lower than the PHF alone samples (p < 0.0001). Ab→ PHF cells were not reduced relative to PHF alone. d IgG did not prevent
against significant increases in total tau after exposure to PHF. e As above, the ratio of tau/NeuN was determined, and again this ratio was
significantly increased in PHF alone samples relative to control cells (1.6 fold increase, p < 0.0001). Neurons treated with 4E6 in the PHF + Ab and
PHF→ Ab, but not Ab→ PHF groups had significantly lower corrected tau levels compared to the PHF alone groups (p < 0.0001). f When
adjusted for NeuN levels tau levels in the PHF + Ab, PHF→ Ab, and Ab→ PHF control IgG groups were 0.98, 1.4 and 1.3 fold higher than control,
and not significantly different from PHF alone
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lower than the PHF alone samples and comparable to
untreated controls (p < 0.0001 for both, Fig. 9g). As
with the uncorrected values, none of the 6B2 (Fig. 9h)
or IgG1 (Fig. 9i) groups, or the 4E6 Ab→ PHF group,
were different from PHF alone.
PHF 1 μg ANOVA results revealed significant effects of
dosing method and time (p < 0.0001 for both; see
Fig. 10a, b for immunoblots). PHF alone samples under
the 1 μg/ml dosing conditions had significantly higher
phospho-tau levels than untreated control cells (65 %
Fig. 9 4E6, but not 6B2, prevented the increase in the phosphorylated tau/NeuN ratio caused by exposure to 10 μg/ml PHF. a–c Samples
probed with a polyclonal antibody recognizing tau phosphorylated at Ser199 from cells exposed to PHF alone or PHF in combination
with a 4E6, b 6B2 or c control IgG1. d PHF alone samples had significantly reduced phospho-tau levels relative to untreated cells (34 %
reduction, p < 0.05). For 4E6, both the PHF + Ab and PHF→ Ab treatment groups had significantly higher phospho-tau levels than the PHF
alone group (p < 0.001 and 0.05 respectively). e In samples treated with a combination of PHF and 6B2, none of the treatment groups
were significantly different from PHF alone. f As with 6B2, uncorrected IgG1 samples showed no significant difference relative to PHF
alone. g Correcting for NeuN levels to take PHF toxicity into account, PHF alone samples had higher ratio of P-Ser199/NeuN, compared
to untreated controls (a 4.1 fold increase, p < 0.0001). Phospho- tau levels in the 4E6 PHF + Ab and PHF→ Ab groups were significantly
lower than the PHF alone samples (91 and 78 % of untreated controls, p < 0.0001). h When corrected for NeuN levels, 6B2 treated cells
were not significantly different from PHF alone samples. i When NeuN levels were considered, IgG1 samples were also not significantly
different from PHF alone
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above control at day 7, p < 0.0001). Again, 4E6 was ef-
fective in preventing PHF-induced pathological changes
under the PHF + Ab and PHF→Ab dosing conditions.
Both groups had significantly lower phospho-tau levels
than PHF alone at levels comparable to untreated
controls (p < 0.0001 for both, Fig. 10c). However, under
the Ab→ PHF dosing conditions, 4E6 was ineffective at
reducing phospho-tau levels. None of the IgG1 groups
(Fig. 10d) differed compared to the PHF alone samples.
Phospho-Tau/NeuN Controlled for NeuN levels, these
differences remained. As above, dosing method and
time produced significant effects by two-way ANOVA
(p < 0.0001 for both). The phospho-tau levels in the
PHF alone samples were 1.5 fold higher than that of
the untreated control cells by experimental day seven
(p < 0.0001). Of the 4E6 dosing paradigms, the PHF +
Ab and PHF→Ab groups had tau levels comparable
to untreated controls and significantly lower than
those seen in the PHF alone samples (p < 0.0001 for
both, Fig. 10e). As above, none of the IgG1 groups
(Fig. 10f ) differed from PHF alone samples.
Together, the total and phospho-tau data show that
PHF addition to the cultured neurons increases the
levels of these forms of tau in the neurons that survive
PHF toxicity. The 4E6 antibody, in addition to prevent-
ing PHF-induced toxicity, prevents PHF-induced
increases in both total- and phospho-tau, under the
PHF + Ab and PHF→Ab conditions. As in the LDH
and NeuN toxicity studies, 4E6 Ab→ PHF and all three
dosing conditions of 6B2 and IgG1 were ineffective.
Pattern of PHF and Antibody binding differs depending on
dosing method
To further clarify these efficacy differences, fluorescently
labeled PHF and 4E6 or 6B2 were utilized to examine
Fig. 10 Low dose PHF (1 μg/ml) increased the phosphorylated tau/NeuN ratio, which was prevented by 4E6. a, b Immunoblots of samples
treated with 1 μg/ml PHF alone or with a 4E6 or b IgG1, reacted with a P-Ser199 antibody. c In cells treated with 1 μg/ml PHF and 4E6, the PHF
alone and Ab→ PHF groups showed significantly higher phosphorylated tau levels compared to untreated control samples (165 and 185 %
above control, p < 0.0001 for both). The PHF + Ab and PHF→ Ab groups were significantly lower (91 and 112 % control, p < 0.0001 for both) than
the PHF alone samples. d All of the IgG groups showed significantly higher average phospho-tau levels than the untreated controls (79, 119, and
94 % above control, p < 0.0001 for all) after 7 days. None of the groups were significantly different compared to the PHF alone samples. e As
above, NeuN levels were used to control for cell loss, and the pattern of results seen in 4E6 treated cells remained. The PHF alone and Ab→ PHF
groups had significantly higher phospho-tau/NeuN ratios than untreated samples (1.46 and 1.9 fold higher, p < 0.0001). The PHF + Ab and PHF→
Ab groups had significantly lower phospho-tau levels than the PHF alone samples comparable to untreated controls. f Correcting for NeuN levels,
the same pattern of results in cells treated with control IgG was observed. All groups showed significantly higher levels of phospho-tau/NeuN
relative to untreated controls (2, 3.9 and 1.5 fold increase in the PHF + Ab, PHF→ Ab, and Ab→ PHF groups, p < 0.0001 for all) and no difference
relative to the PHF alone samples
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whether the treatment paradigm affects the pattern and
location of PHF and antibody binding. Primary neurons
were incubated using the same dosing methods de-
scribed above. Confocal images were collected 24 h after
the last treatment was applied. PHF was readily taken up
into neurons and could be seen throughout the cells
after 24 h in culture (Fig. 11a–d). In cells from the
PHF→Ab group, we also observed PHF uptake and
intracellular distribution. Under this dosing regimen,
4E6 was also internalized and co-localized with the pre-
viously added PHF (Fig. 11e–h). However, a different
pattern was observed in the PHF + Ab group. Under
these conditions, PHF and 4E6 were also seen co-
localized, but the PHF-antibody complexes were extra-
cellular (Fig. 11i–l). These results indicate that although
these two dosing methods are effective in reducing
pathological changes associated with PHF addition, the
mechanism of action differs. When cells were incubated
with 4E6 prior to PHF, PHF puncta could be seen in the
cells, but 4E6 was not apparent, indicating that the anti-
body may have been cleared from the cell (Fig. 11m–p).
These results help to explain the inefficacy of this
paradigm.
We also examined binding between 6B2 and PHF.
In the PHF→Ab condition, intracellular colocaliza-
tion was observed, however, in the PHF + Ab condi-
tion the large extracellular PHF-antibody complexes
were not seen (Fig. 11q–x). Rather, we observed
intracellular PHF material, but 6B2 was not present.
In the 6B2→ PHF cells, again the PHF material was
clearly visible, but the antibody was not (Fig. 11Y-BB).
4E6 recognizes primarily solubilized PHF whereas 6B2 binds
mainly to aggregated PHF and sarkosyl insoluble tau
protein
To further clarify these intriguing results, binding of the
antibodies to tau peptides, solubilized PHF and other tau
fractions, was characterized in BIACORE, dot blot and
ELISA assays.
BIACORE assay
Binding to the P-Ser396 peptide was not detected for
either antibody. However, for all other epitope peptides,
6B2 yielded KD values substantially lower (10
−9-10−10 M)
than those seen with 4E6 (10−7 M), indicating much
higher affinity for the immunogen epitope (Table 1).
Dot blot assay
Binding of 4E6 and 6B2 to PHF was first assayed
using a dot blot of different tau fractions (Fig. 4,
Fig. 12). The solubilized PHF-, sarkosyl soluble- and
sarkosyl insoluble fractions from the same human AD
brain were applied to nitrocellulose membrane, which
was then incubated with 4E6 or 6B2 (Fig. 12a). 4E6
had higher affinity for solubilized PHF but 6B2 bound
better to the sarkosyl insoluble fraction. Neither
antibody bound well to the sarkosyl soluble fraction.
Both 4E6 and 6B2 showed limited binding to control
samples using dot blot (Fig. 12b). No visible reactivity
was seen in the sarkosyl soluble fraction, and only
minimal reactivity in the other two fractions. Note
that the control tissue had very limited if any patho-
logical tau and the pelletable material was much less
than in the AD tissue and likely contains various pro-
teins. Same amount of protein was blotted for AD
and control tissue.
Fig. 11 PHF and antibody binding differs depending on antibody
and dosing method. Primary neurons were treated with 10 μg/ml
human derived PHF material alone, PHF and 1 μg/ml 4E6 or 6B2
together (co-incubation), or 24 h PHF incubation followed by 4E6 or
6B2 for an additional 24 h. All coverslips were stained with Dako pan
tau polyclonal antibody. a–d Neurons readily took up the PHF tau
from the media and PHF positive puncta were detected in cell
bodies and neuronal processes. e–h As shown above, PHF was
taken up by the cultured neurons. 4E6 was added 24 h later and
co-localized intracellularly with the exogenous PHF. i–l When added
together, 4E6 and the PHF material formed large extracellular
aggregates. m–p In the 4E6→ PHF group, PHF positive puncta were
detected in the cells, but 4E6 was not. q–t When 6B2 was added
24 h after PHF, we observed intracellular co-localization. u–x Unlike
4E6, coincubation of 6B2 and PHF did not produce the large
extracellular complexes. Y-BB When 6B2 was added before PHF, PHF
but not 6B2 was seen in the cells
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ELISA assays
Two different ELISA assays were performed to assess
binding of 4E6 and 6B2 to different tau fractions from
AD and control brain. In the first, the plate was coated
with material from either the sarkosyl soluble, solubi-
lized PHF or sarkosyl insoluble fractions (1 μg/well) and
dilutions of antibody were added.
When plates were coated with the solubilized PHF
(Fig. 12c), 6B2 showed significantly higher binding to
wells coated with material from AD brain than control
for all dilutions up to 1/125 k (p < 0.0001–0.05) and sig-
nificantly higher binding that 4E6 to either AD or con-
trol at 1/200 - 1/5 k (p < 0.0001). In contrast, 4E6 did
not show significantly higher binding to AD tau versus
control tau at any of the dilutions.
In plates coated with sarkosyl soluble tau (Fig. 12d),
low binding was detected even at the highest antibody
concentrations. At the 1/200 dilution, 6B2 showed sig-
nificantly higher binding to AD tau than tau from con-
trol brain, and also higher binding than 4E6 to either
AD or control tau (p < 0.01, 0.05 and 0.05 respectively).
None of the other dilutions or conditions showed any
significant differences between samples.
Finally, when the plates were coated with the sarkosyl
insoluble tau (Fig. 12e), 6B2 showed significantly higher
binding than 4E6 to AD tau at the 1/200-1/125 k dilu-
tions (p < 0.0001–0.05) and also significantly higher
binding to AD tau at the same dilutions (p < 0.0001–
0.05). Again, there was no significant difference in bind-
ing to AD versus control with 4E6.
A competition ELISA was then performed to deter-
mine antibody binding to PHF in solution. In this assay,
plates were coated with solubilized PHF as described
above, but before antibodies were added aliquots were
incubated for 1 h with increasing concentrations of
solubilized PHF (0.01–1 μg/ml). Under these conditions,
binding to solubilized PHF markedly inhibited binding
of 4E6 to the PHF coated onto the plate, but 6B2 bind-
ing was not affected. At the highest PHF concentration,
4E6 binding to the wells was reduced by 85 %. The IC50
value was determined to be 71 nM (Fig. 12f). In con-
trast, 6B2 did not show reduced binding to the wells at
any PHF concentration. These data indicate that the two
antibodies are binding to different tau species within the
AD-derived PHF material; 4E6 to solubilized PHF and
6B2 to aggregated PHF.
Alone, the ELISA and dot blot binding data are of lim-
ited utility for clarifying the efficacy or lack thereof of
the antibodies. However, combined with findings from
the confocal (Fig. 11l vs. x) and biochemical analyses
(Fig. 3g) suggests that efficacy of 4E6 and lack thereof
for 6B2 may be explained by the degree of interaction/
neutralization of PHF. Dot blot assay and ELISA data
show that although both 4E6 and 6B2 bind to PHF, the
affinity and preferred species differs, with 6B2 potentially
binding to a more highly aggregated but less toxic tau
form (Fig. 12a). In contrast, in all assays 4E6 showed less
binding to aggregated tau and preferentially binds to the
solubilized PHF. Despite strong binding to the solubi-
lized PHF fraction on dot blots relative to control sam-
ples, in ELISA assays 4E6 shows a limited ability to bind
to the tau which is aggregated onto the wells. Ab-PHF
complexes are not seen with the co-incubation of 6B2
and PHF because the latter is in its solubilized form in
the culture media which does not bind 6B2 (Fig. 12f ).
(The solubility of the PHF fraction under experimental
concentrations was confirmed using ultra-centrifugation,
as described in the Methods section.) pH changes in
endosomes/lysosomes may promote aggregation, result-
ing in a mixture of soluble and insoluble forms of PHF
and, therefore, binding of both antibodies in these vesi-
cles (the PHF→Ab condition). However, only binding
of 4E6 to the solubilized PHF form is beneficial whereas
6B2 binding has no effect. This detailed clarification has
major implications for the development of tau immuno-
therapies and for understanding the pathogenesis of
tauopathies.
4E6 reduces the spread of pathological tau between cell
populations
The ability of 4E6 to prevent the spreading of PHF
between cells was assessed using microfluidic axon isola-
tion chambers (Fig. 13a–c shows a schematic of the
chambers and neuron growing in the device). Briefly, Tg
cells in one chamber were treated using one of the dos-
ing paradigms described above and the percentage of
PHF positive WT cells in the opposite chamber was de-
termined (Fig. 13d–f show PHF positive WT cells).
Table 1 Antibody binding to tau peptides
KD (BIACORE) 4E6 6B2
30 amino acid peptides
Tau379-408 [P-Ser396/404] 2.71 × 10−7 3.95 × 10−10
Tau379-408 2.12 × 10−7 2.51 × 10−9
23 amino acid peptides
Tau386-408 [P-Ser396/404] 4.69 × 10−7 2.39 × 10−9
Tau386-408 [P-Ser404] 2.78 × 10−7 4.11 × 10−9
Tau386-408 [P-Ser396] ND ND
The binding of 4E6 and 6B2 to tau peptides corresponding to the 396/404
region of the tau protein was examined using a BIACORE assay. Neither
antibody showed binding to the P-Ser396 which differs from previously
published ELISA assays [11]. Using ELISA, 4E6 bound very poorly to the
P-Ser396 peptide coated onto the plate, however, 6B2 did show binding. This
may be due to conformational changes which occur in the peptide when
binding to the plate, or differences that occur when the antibody is
immobilized. We observed similar lack of binding of 4E6 and 6B2 to the
P-Ser396 peptide in solution in competition ELISAs (data not shown),
confirming the accuracy of the BIACORE data. These findings emphasize that a
variety of methods should be used when assessing antibody affinity
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A one-way ANOVA showed a significant treatment
effect (p = 0.002; Fig. 13g). In the PHF alone treated
cultures, 24 ± 3 % of the WT cells contained fluores-
cently labeled PHF material. When 50 nM of botulinum
toxin was added to PHF treated cultures, this was re-
duced to 4 ± 0.2 % (p < 0.01), indicating that the PHF in
the WT cells gets there via synaptic release. PHF + Ab
also significantly reduced the percentage of PHF positive
WT cells to 15 ± 2 % (p < 0.05). PHF→Ab treatment
groups showed a lower percentage of PHF positive WT
cells, 17 ± 4 % although the results did not reach signifi-
cance. However, as expected based on other results,
there was no significant change in the percentage of
PHF positive WT cells under Ab→ PHF conditions, fur-
ther confirming the inefficacy of this approach.
4E6 is effective intra- and extracellularly in blocking PHF-
induced toxicity and associated tau pathologies
To further investigate whether timing of antibody and
PHF affect the mechanism of action, an additional group
of cells was plated and dosed as described above. How-
ever, when 4E6 was applied to the cultures, 1 μg/ml of
dansyl cadaverine (DC) was added as well (Fig. 14). DC
is an inhibitor of clathrin (receptor)-mediated endocytosis
Fig. 12 4E6 and 6B2 differ in their binding to human derived PHF material. a Different tau species were spotted onto nitrocellulose and
incubated with either 4E6 or 6B2 as the primary antibody. 4E6 bound better to solubilized PHF but 6B2 reacted more strongly with the sarkosyl
insoluble tau fraction. Both antibodies had limited reactivity with sarkosyl soluble tau protein. b The same three tau fractions were prepared from
control brain, and spotted onto nitrocellulose. Neither antibody showed binding to the sarkosyl soluble fraction, and only limited binding to the
solubilized PHF and sarkosyl insoluble tau. (Images for all three samples for the 4E6 and 6B2 treated control brains were taken from the same
strip, the order has been changed for clarity.) c Plates were coated with solubilized PHF from AD and control brains. 6B2 showed significantly
higher binding to AD than control, and than 4E6 to either AD or control at dilutions, 1/200-1/125 (p < 0.0001–0.05). 4E6 did not show significantly
higher binding to AD versus control. d The assay plate was coated with sarkosyl soluble tau from AD and control brains, and serial dilutions of
4E6 and 6B2 were added. At the 1/200 dilution 6B2 showed significantly higher binding to AD than control, and higher binding than 4E6 to
either fraction (p < 0.01, 0.05 and 0.05 respectively). e Assay plates were coated with sarkosyl insoluble tau. 6B2 showed significantly higher
binding to AD relative to control, and than 4E6 to either AD or control, from dilutions 1/200-1/125 k (p < 0.0001–0.05). As before, no significant
differences between AD and control sample were seen with 4E6. f Competitive ELISA assays were performed by pre-incubating the antibodies
with increasing concentrations of solubilized PHF material (0.01 -1 μg/ml). 6B2 binding was not inhibited at any PHF concentration. However, 4E6
binding was inhibited in a dose-dependent manner with an IC50 of 71 nM. All of the results show that 4E6 preferentially binds solubilized tau
species, while 6B2 primarily binds to insoluble highly aggregated tau. All columns or points on each graph have SEM error bars, however some of
those are too small to be visible
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and in previous experiments, not using exogenous PHF,
has been shown to block uptake of 4E6 [10]. Thus, these
experiments allowed us to confirm whether antibody in-
ternalization is required to prevent PHF-induced path-
ology. When total tau levels were examined by
immunoblot, there was no significant difference between
samples incubated with or without DC under either dos-
ing conditions (data not shown). In PHF +Ab samples,
addition of DC did not change NeuN levels (data not
shown) or tau/NeuN ratio (Fig. 14a). However, when cells
in the PHF→Ab condition were incubated with DC, a
significant decrease in NeuN was observed when com-
pared to cells without DC (NeuN reduced to 32 % of con-
trol, p = 0.00005). Further, the ratio of Tau/NeuN was
significantly shifted in the PHF→Ab samples where DC
was added (1.18 for cells without DC and 2.95 for DC
treated cells, p = 0.008; Fig. 14b). These results indicate
that under conditions where 4E6 and PHF are added to-
gether, receptor-mediated internalization (via Fc receptors
based on our prior findings [10]) is unnecessary for the
antibody to prevent PHF induced pathological changes. In
contrast, once the PHF material has been taken up by the
neurons, blocking antibody internalization reduces its effi-
cacy in preventing PHF toxicity.
Discussion
Our findings indicate that two antibodies against the
same epitope region have very different effects on cogni-
tion in a mouse model of early stage tauopathy. Both
antibodies have phospho-selectivity for the immunogen
Fig. 13 4E6 reduced the spread of tau between neurons. a, b Schematic of microfluidic chambers, showing the reservoirs that the cells
were added to. Panel B is a magnification of the box in panel A showing the microgrooves which connect the two reservoirs. c Confocal
image showing axons growing through the microgrooves. Cell is stained with pan-tau antibody. (scale bar = 150 μm) d–f Fluorescently
labeled PHF material (1 μg/ml) was added to the chamber containing JNPL3 cells. Coverslips were fixed and stained with an antibody
recognizing total tau. Stained wild-type neurons from the opposite chamber are visualized in d, and one of them has prominent PHF
puncta in the cell body as seen in E. Merged image of d and e is depicted in F (scale bar = 50). g Neurons in the first chamber were
treated with PHF and 4E6 in combination as described in Fig. 4b. Following addition of the antibody, cells were incubated for a further
72 h. Number of cells in the opposite side containing PHF puncta was recorded. Botulinum toxin was used as a negative control. In the
PHF alone condition, 24 % of cells were PHF positive. Incubation with botulinum toxin reduced this percentage to 4 % (p < 0.01). In the
PHF + Ab group this was reduced to 14.6 % (p < 0.05), and 17.6 % in the PHF→ Ab condition. *: p < 0.05, **: p < 0.01
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but differ in many ways. Interestingly, the lower affinity
antibody, 4E6, is effective in acutely improving spatial
learning and memory and reducing soluble phospho-tau,
whereas the higher affinity antibody, 6B2, is ineffective.
Importantly, we further show identical efficacy differ-
ences in a primary neuronal tauopathy culture model
treated with paired helical filaments (PHF) isolated from
an Alzheimer brain. This indicates that the ex vivo
culture model has similar predictive validity as the
mouse model although the measured parameters are not
comparable.
Modest tau pathology was detected by immunohisto-
chemistry in brains of htau mice, and the treatment and
control groups did not appear to differ. Under such con-
ditions of early stage tau pathology, it is easier to quanti-
tate early tau pathology on western blots than by
immunohistochemistry, and on such blots insoluble tau
protein was clearly present in the 12–13 month old htau
mice. Neither tau antibody induced changes in insoluble
tau levels as measured by human specific tau antibody
(CP27), although 4E6 markedly improved spatial learn-
ing and memory. Analyses of the soluble tau fraction re-
vealed that these cognitive benefits were associated with
reduced levels of phospho-tau protein (PHF-1 reactive).
It is likely that under such acute treatment conditions,
global changes in insoluble tau levels may not be readily
achievable, whereas soluble pathological tau protein
should be more amenable to clearance. Indeed, the PHF-
1 antibody recognizes a phospho-tau epitope within the
same region as 4E6, which may explain why this tau
fraction is preferentially cleared. However, it does not
appear to be oligomer specific clearance, as we did not
observe any differences in T22 immunoblots between
4E6 and IgG-treated mice.
We did not observe a functional rescue of associative
fear memory following acute treatment with either 4E6
or 6B2. There are many possible explanations for this.
First, the training protocol used may have been too
‘strong’ to detect a subtle memory deficit. This may be
particularly important because the overall tau path-
ology that we observed, although present, was mild.
In our prior studies we only detected associative
memory deficits in aged mice with greater levels of
tau pathology [24].
Despite the different model systems used, the findings
obtained from ex vivo and in vivo experiments are con-
sistent and not model dependent, which supports their
validity. In both cases, 4E6 shows efficacy in preventing
tau pathology and associated toxicity/cognitive impair-
ment, while 6B2 does not.
An insight into the relevant tau species was ob-
tained from ELISA and dot blot studies of antibody
binding to soluble, solubilized, or aggregated human
tau species. 4E6 recognizes primarily solubilized PHF,
in an ELISA and dot blot assay, which may explain
lack of more global tau changes in the animals under
such acute conditions. Mice at this age with modest
tau pathology may be ideal to assess acute effects of
therapies, particularly under pairwise cognitive com-
parison as used herein, which improves the sensitivity
of detecting beneficial effects. Such in vivo learning
and memory benefits by 4E6 and lack thereof for 6B2
in the htau mice are in agreement with the efficacy
results in vivo and in the tauopathy culture model.
Interestingly, soluble tau species have recently been
linked to LTP and memory in htau mice [25].
Although the ELISA and dot blot assays provided use-
ful information on the tau binding properties of 4E6 and
6B2, the data obtained from confocal imaging was of
greater value in determining mechanism and possible
explanations for the differences in efficacy. With co-
incubation in the culture assay, extracellular complexes
Fig. 14 Mechanism of action is influenced by dosing method. PHF (10 μg/ml) was added to JNPL3 neurons, with 4E6 added either at the same
time or 24 h later. In additional cultures, 1 μg/ml dansyl cadaverine (DC), an inhibitor of clathrin mediated endocytosis, was also added along
with 4E6 to determine whether antibody internalization is necessary for 4E6 to exert its effects. a In the PHF + Ab treatment group, addition of
DC did not affect the NeuN corrected tau levels, indicating that the antibody is working extracellularly. b When DC was present in the PHF→ Ab
condition, total tau/NeuN ratios was shifted beginning at 24 h, and the relative tau levels were significantly higher after 7 days. Hence, under
these conditions, the antibody is working intracellularly
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of exogenous PHF and 4E6 formed (Fig. 11l) as 4E6
binds to soluble PHF. This complex formation neutral-
ized PHF and prevented its uptake. However, with 6B2,
such complexes did not form, as 6B2 does not bind well
to solubilized PHF, and PHF was detected intraneuron-
ally (Fig. 11x). This indicates that 6B2 could not prevent
PHF uptake and toxicity. These results support that anti-
bodies can be beneficial while working in the interstitial
space between cells. In the living brain, these tau-
antibody complexes could then be taken up and cleared
by microglia as we have seen previously [11] and others
have studied more extensively [26, 27].
Alone, addition of 10 or 1 μg/ml PHF dose-
dependently induced cell loss, as measured using LDH
and NeuN levels, as well as increased total and phos-
phorylated tau in the remaining neurons. It spread be-
tween cell populations, through release and subsequent
uptake by other neurons. To test the efficacy of our anti-
bodies, we utilized three different dosing methods differ-
ing in the timing of tau and antibody administration. For
one of the antibodies, 4E6, two of these methods,
addition of the PHF and antibody together, and addition
of 4E6 24 h after PHF, prevented PHF toxicity, seeding,
and spread. Interestingly, although similarly effective, the
mechanism through which the protection occurs dif-
fered between the dosing paradigms.
When 4E6 or 6B2 were added 24 h after PHF, these
colocalized intracellularly with PHF but only 4E6 pre-
vented PHF toxicity. Based on the confocal data from the
co-incubation experiments, as well as dot blot and ELISA
data, 4E6 binds better to solubilized PHF than 6B2 which
reacts better with aggregated PHF and insoluble tau.
Hence, this feature may explain the intracellular efficacy
of 4E6. It may prevent PHF polymerization, facilitating ac-
cess of lysosomal enzymes to clear PHF and/or directly
neutralizing soluble PHF and preventing toxicity. How-
ever, 6B2-PHF binding may be inert without promoting
disassembly. Furthermore, due to poor binding it may be
unable to prevent PHF fibril formation and/or toxicity of
soluble PHF.
Together, these findings explain the therapeutic effi-
cacy of 4E6. It is capable of both extracellular blockage
and intracellular clearance of PHF. Our previous data
indicates that 4E6 enters the endosomal/lysosomal
system within tauopathy neurons and promotes clear-
ance of native tau, possibly by preventing aggregation
[10, 11, 13]. Other groups have observed internalization
of tau antibodies [9, 12], and lysosomal colocalization
[9]. Further, neuronal colocalization between antibody,
target, and endosomal/lysosomal markers has been seen
for α-synuclein antibodies in a PD mouse model [28]. In
other experiments, tau antibodies are able to block the
uptake of pathological tau or improve experimental out-
comes without apparently entering neurons [15–17].
Whether antibodies are taken into neurons is likely
influenced by several factors including, charge, target
and Fc receptor affinity, and as data presented herein
suggests, location of the target and timing of antibody
addition.
In contrast, pre-incubation with 4E6 was ineffective at
reducing toxicity or seeding of tau pathology. A likely
reason is the relative lack of the target epitope under
these conditions. Previously, we showed that neuronal
4E6 uptake correlates highly with pathological intracellu-
lar tau levels [10]. When the antibody is added first, effi-
cacy requires retention in neurons until PHF addition
24 h later. However, a shortage of the target means the
antibody will remain unbound, and more prone to deg-
radation or recycling out of the cell, as seen via confocal
imaging. Although 4E6 was ineffective under these
conditions, it does not rule out prophylactic administra-
tion of tau antibodies, as circulating antibodies could
prevent disease initiation by clearing early-stage tau
aggregates. Exogenous antibodies have a half-life of one
to three weeks and lower doses could be used in pre-
symptomatic individuals at risk.
Notably, the different efficacies between dosing
methods were also observed in the spreading assay using
the microfluidic chambers. In both model systems, only
the co-incubation dosing or PHF→Ab was effective,
whereas Ab→ PHF was not.
In our previously published findings [11], both 4E6
and 6B2 showed efficacy in preventing increased
phospho-tau levels in a brain slice model, in contrast to
6B2’s ineffectiveness in the primary neurons in the
current study. There are likely multiple factors which
contribute to these differences. In the slice culture sys-
tem, treatment with antibodies lasted for up to 6 weeks
and no exogenous tau was introduced in that system. In
the present experiments, a much shorter time scale is
used (7 days as opposed to six weeks) and we are utiliz-
ing PHF tau isolated from a human AD brain. The tau
found in the PHF fraction also represents a different
stage of tangle formation. Furthermore, the PHF isolated
from the AD brain may have additional posttranslational
modifications not present in the endogenous tau of the
slices. Differences in cell health over the course of the
experiments are likely also influenced by the culture
model. In the primary cultures, neurons lack the trophic
support provided by glial cells, which are present in the
brain slices.
We have shown that antibody uptake into neurons can
be blocked with an antibody against FcII/III receptors or
with dansyl cadaverine, which blocks receptor-mediated
endocytosis [10]. Under the co-incubation conditions,
blocking antibody uptake had no effect on the outcome.
However, when 4E6 was added 24 h after PHF addition,
blocking its uptake prevented its beneficial effects. These
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findings confirm that under co-incubation conditions,
the antibody is working extracellularly but when it is
added 24 h after PHF, its effects are intracellular.
We have previously shown that both antibodies are
taken up into tauopathy neurons in brain slice- and
primary cultures, in which they colocalize with tau
aggregates in the endosomal-lysosomal system [10, 11].
Furthermore, 6B2 and its single chain variable fragment
derivative can be used to image tau lesions in vivo and
end up in the same neuronal compartments after per-
ipheral injection [14]. Such uptake and colocalization is
by itself not an indication of efficacy but we have shown
that prevention of 4E6 neuronal uptake blocks acute
antibody-mediated tau clearance [10]. The culture data
confirms such intracellular clearance and additionally
shows prevention of neurotoxicity by 4E6 in a different
culture model, which is more relevant to human disease
as AD derived PHF material is used. Furthermore, in our
PHF-treated primary culture study, 6B2 was ineffective
under various experimental conditions using multiple
outcome measures. Overall, 4E6 may be better suited as
a therapeutic antibody targeting soluble tau species and
6B2, or ideally its smaller derivatives with better access
to the target, useful as an imaging probe for insoluble
tau lesions.
Specifically, the ex vivo culture model shows that 4E6,
a monoclonal tau antibody targeting the phospho-serine
396/404 region prevented toxicity and reduced tau levels
induced by the addition of Alzheimer’s brain-derived
PHF material. Importantly, another tau monoclonal,
6B2, which has substantially higher affinity for the tau
peptide immunogen and aggregated PHF tau than 4E6,
was ineffective under these experimental conditions.
Further analyses revealed that 4E6 had higher affinity
than 6B2 for the solubilized PHF that was used to pro-
mote toxicity in cultured neurons. This likely explains
the efficacy of the former antibody and lack thereof for
the latter. These findings have major implications for the
development of passive tau immunotherapies. Efficacy
cannot be predicted by affinity to the immunogen alone
or to aggregated tau, but has to be determined in bio-
logical models of tau pathology. Combined with imaging
data, these results provide information on how affinity
and efficacy relate.
Other tau immunotherapy studies have reported effi-
cacy differences between antibodies recognizing epi-
topes of different sequences of tau and one study
between different isotypes of two antibodies of similar
affinity against the same epitope (for review see [5]).
4E6 and 6B2 are of the same isotype, IgG1, and our
findings show for the first time that subtle difference in
epitope recognition can profoundly affect efficacy. Im-
portantly, we have confirmed and provided mechanistic
insight into these in vivo differences in a disease
relevant ex vivo neuronal culture model, in which we
promote tau pathology with Alzheimer’s brain-derived
PHF in primary neurons expressing familial tau muta-
tion. Hence, the contrasting efficacies are seen consist-
ently in different models with or without tau mutation
and may have major therapeutic implications for both
familial and sporadic tauopathies. The models
employed have strong construct and face validity as
they are based on sound theoretical rational as normal
or familial (mutated) human tau is being expressed, and
have the key features associated with tauopathies,
namely tau aggregation, toxicity, and associated cogni-
tive impairments in the animals. The human PHF cul-
ture model has strong predictive validity for the
outcome in the animal model, but it remains to be seen
if this holds up in clinical trials.
Conclusions
Overall, these findings indicate that antibody efficacy
cannot be predicted by affinity to the immunogen alone
or broad reactivity with various typical pathological
forms of tau but has to be determined in biological
models of tau pathology. Binding to solubilized PHF ra-
ther than aggregated PHF or insoluble tau predicts effi-
cacy in these ex vivo PHF seeding and spreading culture
models and in a tauopathy mouse model. 4E6 promotes
clearance of pathological tau and thereby prevents its
toxicity via intra- and extracellular pathways. Such wide
spectrum antibodies are likely to be more efficacious
than antibodies that can only work outside neurons. Im-
portantly, the ex vivo findings fit nicely with acute anti-
body efficacy in vivo in improving cognition, which was
associated with clearance of soluble phospho-tau.
Future studies should consider that relatively subtle
epitope differences, even within the same tau region, can
have major implications for therapeutic outcome, and
that higher affinity for the immunogen or various patho-
logical forms of tau does not necessarily translate into
better efficacy. Considering that antibody humanization
and scale up for clinical trials may alter binding charac-
teristics compared to the original mouse monoclonal
antibody, these findings may have major implications for
ongoing and future clinical trials of tau antibodies.
Methods
Animals and in vivo experimental design
Ex vivo
Pups from the homozygous JNPL3 mouse line (human
0N4R with P301L mutation, Taconic) were collected at
postnatal day zero for primary cultures [29]. This model
was chosen because of its robust tau expression and
phosphorylation even at an early age.
For tau spread experiments, wild type (WT) pups
from the same strain background were also utilized.
Congdon et al. Molecular Neurodegeneration  (2016) 11:62 Page 19 of 24
All breeding animals were monitored closely during the
progression of pregnancy to ensure that pups were col-
lected on the day of birth to make certain that each cul-
ture was at the same developmental age when plated.
In vivo
The htau model (Jackson Laboratories, stock#004808;
[20]), expresses all six isoforms of unmutated human-tau
protein on a null mouse-tau background and develops
progressive tau pathology. This model was utilized in the
whole animal treatment studies due to its more
naturalistic tau expression relative to other tauopathy
models. It was used to assess therapeutic benefits of acute
passive immunotherapy with tau monoclonal antibodies
4E6G7 (4E6) or 6B2G12 (6B2), purified from our hybrid-
oma by Genscript (Paramus, NJ), relative to IgG-injected
(Equitech Bio Inc.) controls. In the 4E6 study, 18 mice (7
males (M) and 11 females (F)) received 4E6 and 18 mice
(8 M and 10 F) control IgG. No animals died during the
study but, four mice in each group were excluded from all
analysis, due to no human-tau expression, despite con-
taining the transgene, leaving 14 4E6 mice (4 M and 10 F)
and 14 IgG mice (7 M and 7 F) for analysis.
In the 6B2 study, only female mice were enrolled, 12
per group. As in the 4E6 study, no animals died during
the experiment, but four IgG-treated and one 6B2-
treated mouse were excluded due to lack of human-tau
expression, leaving 11 6B2 treated mice and 8 IgG
controls for analysis.
At the start of the study, the htau mice were 11–12
months of age and split into two groups with similar
cognitive and motor status before receiving three anti-
body injections and going through retesting on the same
behavioral tests and an additional fear-conditioning test,
followed by brain extraction for tissue analysis. The mice
went through adaptation and pre-tests using Rotarod,
Open Field and Closed Field Symmetrical Tests on days
1–10 as we have detailed previously [30], followed by
antibody injection on days 11 and 14 and retesting on
days 15–18. Third injection was delivered on day 24
followed by fear-conditioning test on days 27–28, and
perfusion on day 30.
All animals were housed at NYU School of Medicine
animal facilities and cared for by the veterinary staff in
AAALAC-approved facilities. All the procedures were
approved by the Institutional Animal Care and Use
Committee (IACUC) committee of the university, and
are in accordance with NIH Guidelines, which meet or
exceed the ARRIVE guidelines.
Isolation of paired helical filaments (PHF)
PHF tau was extracted from the brain of a human AD
patient as described by others [23] but with a few
modifications (See Fig. 4) to create the three fractions
used to treat cells and assess antibody binding via dot
blot. Briefly, the tissue was homogenized in buffer
(pH 6.5; 0.75 M NaCl, 1 mM EGTA, 0.5 mM MgSO4,
and 100 mM 2-(N-morpholino) ethanesulfonic acid) and
centrifuged at 11,000 x g for 20 min to remove debris.
The supernatant was centrifuged for an additional
60 min at 100,000 x g. The resulting pellet was resus-
pended in extraction buffer (10 mM Tris; 10 % sucrose;
0.85 M NaCl; and 1 mM EGTA, pH 7.4) and centrifuged
at 15,000 x g for 20 min. The supernatant was retained
and incubated with 1 % sarkosyl at room temperature.
This supernatant was then centrifuged for 60 min at
100,000 x g. The supernatant from this step was retained
and designated the sarkosyl soluble fraction. The pellet
was resuspended in 50 mM Tris–HCl buffer and desig-
nated the sarkosyl insoluble fraction. For the cell culture
experiments this fraction was first heated briefly to 37 °
C and then dialyzed in PBS, yielding the enriched PHF
fraction. The heating and dialysis promote solubility and
result in solubilized enriched PHF tau fraction which
was used in the experiments. Under our conditions, the
PHF fraction is soluble at the doses used (1 and 10 μg/
ml). Prior work by others indicates that PHF can be sol-
uble at least up to 100 μg/ml [23]. In addition, other
groups have demonstrated that dilution of tau filaments
leads to their disassembly [31–33].
In order to assess the solubility of the PHF material at
the concentrations used, we prepared a 10 μg/ml solu-
tion and subjected it to centrifugation at 100,000 x g for
60 min. Following this spin, the supernatant was re-
moved. Under these conditions, no visible pellet was
seen.
Brain tissue from a control brain was processed in the
same way. Note that the control tissue has very limited
if any pathological tau and the pelletable material is
much less than in the AD tissue and likely contains vari-
ous proteins. Same amount of protein was used in each
assay for AD and control tissue.
ELISA assays
ELISA assays were performed as described [11].
Briefly, 96 well plates were coated with one of three
different tau fractions (sarkosyl soluble, solubilized
PHF, or sarkosyl insoluble) derived from either AD or
control brains dissolved in 50 mM carbonate buffer
(pH 9.6). Plates were blocked using Superblock
(Fisher Scientific) for one hour at room temperature.
After blocking, serial dilutions (1/200-1/625,000) of
the antibodies were added to the plate and incubated for
2 h at room temperature. All antibodies were adjusted to
a concentration of 1 mg/ml before dilution. Plates were
washed with 0.1 % TBS-T and HRP-conjugated mouse
secondary antibody (1:5000) was added for one hour.
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TMB peroxidase EIA reagent (Fisher Scientific) was used
to develop the signal and stopped with 2 N sulfuric acid.
Absorbance at 450 nm was read using a BioTek Synergy 2
plate reader.
For the competitive ELISA assays, a single antibody
concentration was utilized (1:1000 dilution of 1 μg/ml
stock). Aliquots of 4E6, 6B2 and IgG1k isotype control
(eBioscience) were incubated for 30 min with increasing
concentrations of the human derived solubilized PHF
material prior to plating.
Fluorescent labeling
4E6 and human derived solubilized PHF material were
labeled using Alexa Fluor 488 and 647 labeling kits, re-
spectively as per kit instructions.
Primary neuronal cultures
Cultures were prepared as described from the cortex
and hippocampus of p0 pups, with all components pur-
chased from Invitrogen unless otherwise detailed [10].
After 24 h in culture, plating media was removed and
neuronal media (Neurobasal A, 1 ml B27, 17 μl basal
medium Eagle) added. As in previous studies, the purity
of the neuronal cultures was assessed using confocal im-
aging. Under these conditions, about 95 % of cells are
neurons (positive for NeuN) [34].
For cultures grown in microfluidic chambers the same
procedure was utilized. Cells from the JNPL3 mice were
plated on one side of the axon isolation device, and were
allowed to incubate for 72 h. Following this period,
brains from WT animals were harvested and those cells
plated on the opposite side.
Ex vivo experimental design
Primary neuronal cultures were prepared as described
and allowed to recover in culture for one week prior to
treatment [10]. Cells were incubated with either 1 or
10 μg/ml of the human derived PHF material, with cells
and culture media collected at 1, 2, 3, 5 and 7 days. For
cultures being treated with a combination of PHF and
antibody (4E6, 6B2, or IgG), three different treatment
strategies were used. In the first, PHF material was
added and allowed to incubate with the cultures for
24 h. Following this period, the cells were washed with
neuronal media, and fresh media containing 1 μg/ml of
antibody was added (PHF→Ab). In the second, PHF
material and antibody were added to the culture media
simultaneously (PHF + Ab). The third dosing strategy is
the inverse of the first, antibody was added 24 h prior to
PHF (Ab→ PHF). See Fig. 4 for a summary of dosing
methods. In experiments using dansyl cadaverine (DC;
Fisher Scientific), the same methods were employed with
1 μg/ml DC added along with the antibody.
LDH assays
Media was collected from all treatment groups after
seven days in culture. LDH levels in the media were
determined using a Roche cytotoxicity detection kit.
Values obtained from treated samples were compared
to media collected on day zero to assess toxicity.
Media from a set of untreated cells was also collected
to examine the normal changes in cell health over the
culture period. Treated samples, controls and blanks
were added to a 96 well plate and the detection re-
agents were added as per the instructions. Plates were
incubated for 20 min at 37 °C and read using a Bio-
Tek Synergy 2 plate reader.
Microfluidic chambers and tau spreading
Following the addition of the WT cells, cultures were
given one week in culture to stabilize. The same three
treatment methods were utilized. PHF and 4E6 (1 μg/
ml each) were added to the chamber containing
JNPL3 cells, while the opposing chamber containing
WT cells was left untreated. As a negative control,
one group of cells was incubated with 1 μg/ml of the
PHF material and 50 nM of botulinum toxin (gener-
ously provided by Dr. Edwin Vasquez-Cintron, NYU
School of Medicine). The toxin was chosen due to its
ability to prevent membrane fusion and the release of
membrane bound vesicles, and thus prevent release of
PHF tau into the opposite chamber. In neuronal cul-
tures, botulinum toxin has also been shown to pre-
vent the spread of mutant huntingtin by blocking
synaptic vesicle release [35]. In all groups, after the
final treatment, cells were maintained in culture for a
further 72 h. Coverslips were then fixed and stained
for antibodies recognizing total tau. The percentage
of cells in the contralateral chamber containing la-




Following behavioral testing, mice were anesthetized
with ketamine/xylazine (250 mg/50 mg per kg body
weight, intraperitoneally (i.p.)), and processed as we have
described previously [36]. Immunostaining was per-
formed on the right hemisphere of coronal fixed brain
sections (40 μm) with mouse-monoclonal tau antibodies
that stain pathological tau, PHF-1(1:1000), against the P-
Ser396, 404 epitope and MC1 (1:100) which recognizes a
conformational epitope. Both antibodies were generously
provided by Peter Davies (Feinstein Institute for Medical
Research, Manhasset, NY).
Cultures
Performed as previously described [10].
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Immunoblotting
Animals
The left hemisphere of the brain was homogenized in
(5x vol/w) modified RIPA buffer as described [24].
The brain homogenate was centrifuged (20,000xg) for
20 min at 20 °C and supernatants collected as LSS
(Low Speed Supernatant). After protein quantification,
the volumes were adjusted for equal protein concen-
tration with dilution in modified O+ buffer as de-
scribed [24], boiled for 5 min, and loaded onto 12 %
polyacrylamide gel. For the sarkosyl insoluble fraction,
10 % sarkosyl solution was added to LSS, and the
sample mixed for 30 min at room temperature, then
centrifuged at 100,000xg for 1 h at 20 °C. The pellet
was then washed in 1 % sarkosyl solution and spun
again for 100,000xg for 1 h at 20 °C. It was then air
dried for 30 min, mixed with 50 μl of modified O+
buffer, vortexed for 1 min, then boiled for 5 min and
denoted the sarkosyl pellet (SP) fraction. The LSS and
sarkosyl insoluble fractions were both incubated with
CP27. The LSS fraction was also probed for total tau
using Tau-5, phospho-tau using PHF-1 and oligomeric
tau using T22 [37]. All soluble tau blots were normal-
ized using GAPDH.
Cultures
Performed as described previously [10]. Prior to
immunoblotting, all samples from control and treated
cells were assayed for total protein concentration, and
normalized accordingly. Neuronal cultures were
probed with antibodies recognizing neuronal marker
NeuN, total tau (Dako) and tau phosphorylated at
Ser199 (SantaCruz). NeuN was used to measure PHF
induced cytotoxicity [38–43] and to control for tau
levels [44]. Because the expression of tau protein can
vary between animals, even when on a homozygous
background, each experiment was preformed using
cells prepared from a single animal. Untreated control
cells for each experiment were also prepared using
the same animal. Thus, each experiment has its own
unique set of control samples.
Behavioral studies
Sensorimotor tests
Rotarod This test is used to measure forelimb and hind-
limb motor coordination and balance. This procedure
was designed to assess motor behavior without a prac-
tice confound. It was performed similar to as previously
described in detail [30].
Locomotor activity This test was performed similarly to
those previously described in detail [30].
Cognitive tests
Closed field symmetrical maze
This apparatus is a rectangular field, 65 cm square with
10 cm high walls divided into 36 squares. Two boxes,
(16 × 23 × 10 cm), are attached to the square at its diag-
onal corners. The symmetrical maze is a modification of
the Hebb-Williams and Rabinovitch-Rosvold tests as we
have described [30, 45, 46]. Briefly, each end box func-
tions as both a start box and a goal box. The mice run
in opposite directions on alternate trials, thereby elimin-
ating intertrial handling which should minimize stress.
The barriers are placed in the field in symmetrical pat-
terns, so that mice face the same turns going in either
direction within a given problem. On day 0, mice were
adapted to a water-restriction schedule (2 h daily access
to water) and habituated in the same environment as
used for testing. On day 1, all mice were given
saccharine-flavored water, for 10 min in each box. On
day 2, they were placed in the start box and permitted to
explore the field and enter the goal box, in which the
saccharine-water reward (0.05 ml) was available. The
door to each box was manually opened and closed to
allow entry and exit. When the mice were running reli-
ably from the start box to the goal box, they were given
four practice trials under the same condition. On day 3,
they were given one practice session on a simple prob-
lem, in which two barriers were placed in different sym-
metrical positions in the field so as to obstruct direct
access to the goal box. This practice test was repeated
for 4 trials. On day 4, formal testing consisted of three
barriers graded for the most difficulty (Maze 7), based
on our prior findings [30, 45, 46]. Mice were given five
trials with an intertrial interval of 2 min. Performance
was scored manually by the same observer, who was
blinded to the treatment received, in terms of errors (ie,
entries and reentries into designated error zones) and
time to complete each trial.
In the acute treatment study, mice were then split into
control and treatment group, which had similar average
tests scores and group variance, taking into account as
well their performance on the sensorimotor tests. The
mice were retested without practice period after the
treatment period.
Fear-conditioning
This test was performed as described previously [24].
On the training day, mice were allowed to explore for
2 min in the test chamber. The conditioned stimulus
(CS; a white noise 80 dB sound) was presented for 30 s
and followed immediately by a mild foot shock (2 s,
0.5 mA) that served as the unconditioned stimulus (US).
After 2 min, the mice received a second CS-US pairing.
The Freeze Frame monitor system (San Diego Instru-
ments) was used to control the timing of CS and US
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presentations and to record freezing behavior. During
the conditioning procedure, response to the foot shock
-typically run, jump, or vocalize- were also recorded.
Mice were tested for contextual fear in 3 h for short
term memory and 24 h for long term memory, during
which mice were placed into the original test chamber
for 5 min in the absence of CS and freezing behavior
was recorded.
Statistics
All data were analyzed with GraphPad Prism 6 (San
Diego, CA).
Ex vivo culture
In the competitive ELISA assay, data from the group that
did not receive PHF was used to represent 100 % of the
normal binding to the plate, with the other conditions
normalized to these values. Values were fitted to a non-
linear curve competitive binding formula to determine the
IC50 for each antibody. LDH data were analyzed using a
one-way AVOVA. Data from PHF and antibody time
courses were normalized using untreated cells from the
same animal. For each individual time point, the percent-
age of the control for each sample was determined, and
the average and standard error of the mean calculated.
For each set of experiments a two-way ANOVA was used
to determine the effect of individual treatment group and
time. For tau spreading experiments, the percentage of
PHF positive cells in each image was determined, and
used to determine the average and standard error of the
mean for each group. Treatment groups were then com-
pared using a one-way ANOVA. Significant differences be-
tween individual time points, and/or groups, were
determined using Tukey’s multiple comparisons test.
In vivo
The behavioral data with pre- and post-testing (CFSM,
Rotorod and Open Field) was analyzed by a paired t-
test. The Fear Conditioning data and tau levels on west-
ern blots were analyzed with an unpaired t-test. Two
tailed t-tests were used to compare immunoblot results.
Welch correction was used if the data failed a test of
equal variance. When data failed two out of three nor-
mality tests (KS, D′Agostino & Pearson omnibus, and
Shapiro–Wilk normality tests) non-parametric Mann–
Whitney test was used. The effects of gender and anti-
body treatment on behavior and immunoblot results
were further assessed using a two-way ANOVA.
Additional file
Additional file 1: Figure S1. htau mice show limited tau pathology
which is not affected by 4E6 treatment. (PDF 79 kb)
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